Suggested remit: To appraise the clinical and cost effectiveness of nerandomilast within its marketing authorisation for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6446
Provisional Schedule
- Committee meeting:
- 15 July 2026
- Expected publication:
- 25 September 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
- External Assessment Group:
- Health Economics Research Unit and Health Services Research Unit, University of Aberdeen
Stakeholders
- Companies sponsors
- Boehringer Ingelheim
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Action For Pulmonary Fibrosis
- Asthma + Lung UK
- British Society of Rheumatology
- European Lung Foundation
- NARA – The Breathing Charity
- National Rheumatoid Arthritis Society
- Pulmonary Fibrosis Trust
- Pulmonary Hypertension Association UK
- Scleroderma & Raynaud’s UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Versus Arthritis
- Professional groups
- Association of Respiratory Nurse Specialists
- Association for Respiratory Technology and Physiology
- British Geriatrics Society
- British Institute of Radiology
- British Paediatric Respiratory Society
- British Thoracic Society
- Interstitial Lung Disease Interdisciplinary Network
- National Heart and Lung Institute
- Neonatal and Paediatric Pharmacists Group
- Primary Care Respiratory Society UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics & Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Amarox (pirfenidone)
- Aspen (azathioprine)
- Axunio Pharma (pirfenidone)
- Baxter Healthcare (cyclophosphamide)
- Biogen Biosimilars (infliximab)
- Boehringer Ingelheim (nintedanib)
- Celix Pharma (pirfenidone)
- Celltrion Healthcare (infliximab, rituximab)
- Cipla EU (methotrexate)
- Dr Reddy’s Laboratories (pirfenidone)
- Esteve Pharmaceuticals (methotrexate)
- Glenmark Pharmaceuticals Europe (pirfenidone)
- Hospira UK (methotrexate)
- Janssen-Cilag (infliximab)
- Laboratorios Liconsa (pirfenidone)
- Medac Pharma (methotrexate)
- Morningside Healthcare (methotrexate)
- MSN Laboratories Europe (pirfenidone)
- Mylan (azathioprine)
- Nordic Pharma (methotrexate)
- Nova Laboratories (azathioprine)
- Novartis Pharmaceuticals (mycophenolate)
- Novumgen (pirfenidone)
- Orion Pharma UK (methotrexate)
- Pfizer (infliximab, rituximab)
- Roche (mycophenolate, pirfenidone, rituximab)
- Rosemont Pharmaceuticals (methotrexate, mycophenolate)
- Sandoz (azathioprine, infliximab, methotrexate, mycophenolate, pirfenidone, rituximab)
- Seacross Pharmaceuticals (cyclophosphamide)
- Strides Pharma UK (azathioprine)
- Teva UK (mycophenolate, pirfenidone)
- Tillomed Laboratories (azathioprine, mycophenolate)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Chest, Heart and Stroke Scotland
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Northern Ireland Chest, Heart and Stroke Association
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Asthma, Allergy and Inflammation Research Charity
- Breathing Matters
- British Association for Lung Research
- BRONCH-UK
- Cochrane Airways Group
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 December 2025 | Invitation to participate |
| 03 September 2025 - 01 October 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6446 |
| 03 September 2025 | In progress. Scoping commencing |
| 12 December 2024 | Referral |
| 11 October 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early December 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-February 2026. |
| 23 May 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 23 May 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual